Dr Suresh Kuppuswamy
VP-Corporate Development,

2017 An Inflection Point in Growth Trajectory

The past year has been a remarkable one for Skanray and we look forward to close this fiscal on a high note, aided by new initiatives on various fronts. Building on the current momentum, we hope to significantly scale the business in 2017 and continue our good work in providing excellent services to our customers.

The year 2016 was marked by acquisitions, new product launches, and a revamp of the sales and distribution network. The acquisition of Mectron India provided access to a wide range of products and helped complete our offerings to the dental market. Another acquisition of significance includes that of Denmark-based Cardia International, which will help strengthen our presence in the cardiology segment.

New products in radiology, surgical imaging, cardiology, dental, anesthesia, ventilation, and monitoring segments will be launched in the next few months, which will open up certain markets for Skanray and enable our customers to choose the right product that matches their requirement. We will be closer to realizing Total Healthcare Solutions as we progress through 2017 and add ultrasound and piezosurgery to our portfolio. Products that combine diagnostic modalities will be the dominant technology in the next few years, and we have already started to work in this direction. Several new initiatives have been launched to enable our customers have a pleasant experience in buying and maintaining their equipment. Single-point-of-contact for all products ensures that the customer will get swift response for all their support requirements. Life-time service guarantee, quick support, and customer-friendly service policy have been the foundation of our success story. Product-as-a-service program was launched last year and has been generating good response. We intend to build on this program and include more products which will enable asset-light hospitals to maintain lean biomedical resources and be covered against technology obsolescence. Some of our products have been made available for online purchase on various e-commerce sites for the convenience of our customers.

With more than 700 healthcare professionals and 150 dedicated R&D engineers in India and Europe, Skanray is well positioned to build a respectable position in the global medical equipment community. Ever since the commercial launch of the first product in 2011, we have been quite successful in adding several CE and FDA-approved products to the portfolio in a short span of time. Today, the number of products from Skanray is well above 50 and we look forward to add more in the next few months.

Skanray’s Partner and Complement model of working with the global MedTech companies has been hugely successful. We have partnered with some of the largest companies in successfully launching value-segment products and continue to attract more interesting partnerships. The largest contribution to our growth is projected to come from the expansion in export markets. Skanray already has set-up manufacturing and R&D units in Bangalore, Bologna, Sao Paulo, Mysore, and Mexico City. With an installed base presence in more than 80 countries, the focus will now be on establishing our presence in new markets and aggressive penetration in the already existing ones.

The year 2017 will be an inflection point in our growth trajectory as the environment has turned conducive for us to exploit our R&D, manufacturing, and marketing skills to the maximum potential. With a revamped sales network, new product launches, and an aggressive global expansion plan, we are set to grow into one of the finest medical technology brands in the world.

Share this:
Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.